Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the C …
S Kannan, KM Pantalone, S Matsuda… - Journal of …, 2016 - Wiley Online Library
摘要背景当前这项研究的目的是在联合使用二甲双胍(metformin, MF) 与另外一种降糖药物进行
治疗的2 型糖尿病患者中评估总死亡率, 冠心病(coronary artery disease, CAD) …
治疗的2 型糖尿病患者中评估总死亡率, 冠心病(coronary artery disease, CAD) …
Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus
T Li, R Providencia, N Mu, Y Yin, M Chen… - Cardiovascular …, 2021 - Springer
Background Metformin is a first-line drug in type 2 diabetes mellitus (T2DM) treatment, yet
whether metformin may increase all-cause or cardiovascular mortality of T2DM patients …
whether metformin may increase all-cause or cardiovascular mortality of T2DM patients …
Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes: 在新诊断的2 型 …
摘要背景伴随2 型糖尿病患者的心血管事件以及死亡率风险与吸烟状态和同时使用二甲双胍之
间的关系目前尚未十分明确. 方法: 这是一项在82205 名患有2 型糖尿病的患者中进行的队列 …
间的关系目前尚未十分明确. 方法: 这是一项在82205 名患有2 型糖尿病的患者中进行的队列 …
Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes …
HT Ou, YT Chen, YM Liu, JS Wu - Diabetes Research and Clinical Practice, 2016 - Elsevier
Objective To assess the cost-effectiveness of metformin-based dual therapies associated
with cardiovascular disease (CVD) risk in a Chinese population with type 2 diabetes …
with cardiovascular disease (CVD) risk in a Chinese population with type 2 diabetes …
[HTML][HTML] Risk of death and heart failure among patients with type 2 diabetes treated by metformin and nonmetformin monotherapy: a real-world study
S He, X Qian, Y Chen, X Shen, B Zhang… - Journal of Diabetes …, 2021 - hindawi.com
Background. To assess the association of metformin monotherapy with the risk of all-cause
deaths and cardiovascular deaths and events in type 2 diabetes patients in real clinical …
deaths and cardiovascular deaths and events in type 2 diabetes patients in real clinical …
Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South …
YY Cho, SI Cho - Metabolism, 2018 - Elsevier
Aims We explored the risks associated with metformin plus sulfonylurea (MET+ SU) or MET
plus a dipeptidyl peptidase-4 inhibitor (MET+ DPP4i) for hypoglycemia, cardiovascular …
plus a dipeptidyl peptidase-4 inhibitor (MET+ DPP4i) for hypoglycemia, cardiovascular …
Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients
Background Many factors influence whether the first-line oral anti-diabetic drug, metformin,
should be initiated to a patient with type 2 diabetes mellitus (T2DM) early in the course of …
should be initiated to a patient with type 2 diabetes mellitus (T2DM) early in the course of …
Risk of major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality for widely used antihyperglycemic dual and triple therapies for type 2 …
OBJECTIVE The vast number of antihyperglycemic medications and growing amount of
evidence make clinical decision making difficult. The aim of this study was to investigate the …
evidence make clinical decision making difficult. The aim of this study was to investigate the …
Cardiovascular risks associated with second‐line oral antidiabetic agents added to metformin in patients with type 2 diabetes: a nationwide cohort study
YC Chang, LM Chuang, JW Lin, ST Chen… - Diabetic …, 2015 - Wiley Online Library
Aim To compare the cardiovascular risks associated with second‐line oral antidiabetic
agents added to initial metformin therapy in a large nationwide observational study. Methods …
agents added to initial metformin therapy in a large nationwide observational study. Methods …
Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of …
F Wang, Y He, R Zhang, Q Zeng, X Zhao - Medicine, 2017 - journals.lww.com
Background: Clinical trials assessing the combination therapy of metformin plus dipeptidyl
peptidase-4 inhibitors versus metformin plus Sulfonylureas on risk of cardiovascular …
peptidase-4 inhibitors versus metformin plus Sulfonylureas on risk of cardiovascular …